Summit Therapeutics Inc.
SMMT
Rankning i aktier
#1671
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aktiekurs
$15.93
Marknadsvärde
$12.71B
Förändring (1 dag)
-0.97%
Förändring (1 år)
-14.97%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
P/B-tal för Summit Therapeutics Inc. (SMMT)
P/B-tal per October 2026 TTM: 18.69
Enligt Summit Therapeutics Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 18.69. I slutet av 2023 hade företaget ett P/B-tal på 20.82.
Historik för P/B-tal för Summit Therapeutics Inc. från 2004 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 18.69 | -43.35% |
| 2024 | 32.99 | 58.49% |
| 2023 | 20.82 | 220.87% |
| 2022 | 6.49 | 117.76% |
| 2021 | 2.98 | -27.56% |
| 2020 | 4.11 | 536.54% |
| 2019 | 0.65 | -98.56% |
| 2018 | 45.00 | -138.35% |
| 2017 | -117.33 | -1,034.33% |
| 2016 | 12.56 | 5.70% |
| 2015 | 11.88 | -48.78% |
| 2014 | 23.20 | 2.85% |
| 2013 | 22.55 | 13.41% |
| 2012 | 19.89 | -52.35% |
| 2011 | 41.73 | 29.00% |
| 2010 | 32.35 | 6.43% |
| 2009 | 30.39 | 569.58% |
| 2008 | 4.54 | -3.53% |
| 2007 | 4.71 | -38.65% |
| 2006 | 7.67 | 60.25% |
| 2005 | 4.79 | -99.36% |
| 2004 | 747.02 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -66.55% |
US
|
|
| 13.2547 | -29.08% |
US
|
|
| 4.208 | -77.48% |
AU
|
|
| 6.1824 | -66.92% |
NL
|
|
| - | - |
CH
|
